Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of Type 2 Diabetes~* Stable dose of metformin for more than 8 weeks~Exclusion Criteria:~* Subjects with Addison's disease or Cushing's Syndrome~* Type 1 diabetes mellitus or secondary forms of diabetes~* Subjects with uncontrolled thyroid disease~* History of renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 5 mg QD and Metformin
- Treatment B - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 15 mg QD and Metformin
- Treatment C - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 50 mg QD and Metformin
- Treatment D - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 100 mg QD and Metformin
- Treatment E - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 200 mg QD and Metformin
- Treatment F - Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).